Article
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Nov 2010
Blum K A, Jung S-H, Johnson J L, Lin T S, Hsi E D, Lucas D M, Byrd J C, Cheson B D, Bartlett N L
Abstract excerpt
BACKGROUND: Based on in vitro synergistic cytotoxicity when anti-CD30 antibodies are combined with gemcitabine, the Cancer and Leukemia Group B conducted a double-blind, randomized, phase II trial of SGN-30 with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD) in patients with relapsed Hodgkin's lymphoma. PATIENTS AND METHODS: In part 1 of the trial, 16 patients received SGN-30 with GVD to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.